TUG1 and breast carcinoma: In conclusion, artesunate has the potential to modulate the malignant progression of breast cancer cells through the lncRNA TUG1/miR-145-5p/HOXA5 axis, offering promising evidence for its future application in clinical trials for breast cancer treatment.